year left
short interest float
ep becam publicli trade august
clinic stage biopharma compani focus licens
develop chimer antigen receptor cell car-t cancer therapi util genet
modifi patient-deriv lymphocyt recogn elimin tumor cell use
car-t therapi cancer valid recent approv target car-
treatment novarti kymriah gilead yescarta mustang divers pipelin
car-t candid use solid liquid tumor initi clinic candid
target preclin develop
psca mustang led experienc manag team includ dr
manuel litchman ceo senior vice presid execut global program
head novarti kymriah first approv car-t therapi
point discuss
mustang divers portfolio car-t therapi mustang licens
technolog citi fred hutchinson cancer research center
harvard univers initi clinic candid develop
antigen preclin develop psca
mustang report activ phase studi acut
myeloid leukemia aml blastic plasmacytoid dendrit cell neoplasm bpdcn
glioblastoma multiform gbm addit posit clinic data
use target car-t therapi gener research china
note knowledg mustang compani time
target us clinic develop
target car-t relapsed/refractori aml bpdcn
car-t therapi util
costimulatori domain develop patient acut myeloid leukemia
aml blastic plasmacytoid dendrit cell neoplasm bpdcn form cancer
high cell surfac express target partial valid
clinic respons seen compet therapi stemlin
cellecti citi current evalu phase studi
patient relapsed/refractori aml bpdcn mustang plan begin
studi treatment late initi result studi
show complet respons treatment occur aml patient
bpdcn patient next updat program expect
complet build-out worcest cell process facil
start phase i/ii studi metastat breast cancer brain
preliminari phase i/ii result r/r b-cell nhl
 updat data aml bpdcn
ind mustang led phase i/ii studi aml bpdcn
late ind phase i/ii studi multipl myeloma
analyst certif disclosur pleas see page
target car-t us clinic develop third gener
autolog car-t-cel therapi phase i/ii develop r/r b-cell non-hodgkin lymphoma
mustang open patient accrual trial target car-t therapi
knowledg us clinic develop could signific valu driver mustang clinic
investig support clinic activ use target car-t therapi china
phase iia studi china evalu autolog car-t patient r/r b-cell lymphoma
fail prior line therapi orr treat patient achiev
complet respons cr median greater month patient experienc cr month
importantli sever toxic observ could point differenti target
car-t therapi b-cell malign addit could use patient progress
target car-t therapi kymriah yescarta poor candid target treatment thu
sever potenti patient popul could use
target treatment relapsed/refractori glioblastoma multiform
second-gener car-t recogn membrane-teth ligand
develop glioblastoma multiform gbm citi evalu treatment open-label non-
random phase studi patient r/r gbm result use intracerebroventricular icv administr
old patient highli aggress recurr gbm studi publish new england journal
medicin decemb patient poor prognosi achiev complet resolut intracrani
spinal lesion follow icv infus car-t cell provid evid target
result clinic respons
promis car-t therapi highlight recent deal use car-t therapi cancer
valid approv target car-t treatment novarti kymriah gilead yescarta
industri enthusiasm technolog highlight recent acquisit kite pharma
juno billion billion respect overal expect car-t therapi becom
import therapeut option multipl form cancer collabor partnership acquisit
worth note discuss within report
privat placement nasdaq list februari mustang complet million privat
placement financ prior fee expens opn capit market subsidiari nation hold corpor
nhld act sole placement agent financ commenc trade
nasdaq global market symbol august
first quarter result first quarter report research develop
expens million compar million period gener administr
expens total million versu million net loss attribut common
stockhold quarter million per share compar net loss million per
share period march mustang consolid cash cash equival short-
term invest restrict cash million
fortress biotech relationship mustang found fortress biotech fbio hold super-
major posit subsidiari busi model fortress gain valu fortress
compani four-fold
fortress receiv fully-dilut outstand equiti annual fortress compani
fortress receiv royalti net sale fortress compani exclud journey
consolid revenu
fortress receiv annual consult fee fee increas million annual
subsidiari hold net asset greater million begin given calendar year
fortress receiv amount subsidiari common stock equal gross amount equiti
debt financ rais fortress compani
tabl content
engin manufactur car-t candid
allogen car-t collabor
treatment develop aml bpdc
treatment non-hodgkin lymphoma
compet treatment develop r/r nhl
direct car-t gbm
pathogenesi molecular basi gbm
diagnosi screen offici gbm treatment guidelin
treatment develop gbm
target express cancer cell gbm
intellectu properti licens deal
risk invest
clinic stage biopharma compani focus licens develop chimer
antigen receptor cell car-t cancer therapi util genet modifi patient-deriv lymphocyt
recogn elimin tumor cell cell play import role limit tumor growth prolong surviv
cancer patient howev natur anti-tumor activ limit technolog overcom limit
gener larg number cell ex vivo engin chimer tumor associ antigen taa
receptor capabl induc sustain robust anti-tumor activ combin high affin taa receptor
intracellular signal domain singl molecul use car-t therapi cancer valid
approv target car-t treatment novarti kymriah gilead yescarta
industri enthusiasm technolog highlight recent acquisit kite pharma juno
therapeut billion billion respect
mustang divers pipelin car-t candid use solid liquid tumor compani licens
technolog citi fred hutchinson cancer research center harvard univers initi
clinic candid develop antigen preclin
develop psca mustang report activ phase studi
acut myeloid leukemia aml blastic plasmacytoid dendrit cell neoplasm bpdcn
glioblastoma multiform gbm addit posit clinic data use target car-t therapi
gener research china note knowledg mustang compani time
target us clinic develop mustang led experienc manag includ dr manuel
litchman ceo senior vice presid execut global program head novarti kymriah ctl-
first approv car-t therapi mustang development pipelin shown figur note
compani subsidiari fortress biotech fbio term relationship describ
financi manag section report
addit mustang recent in-licens technolog harvard univers establish research
collabor beth israel deaco medic center develop next-gener car-t treatment leverag
capabl gene edit mustang plan explor allogen off-the-shelf car-t candid
collabor
clinic success checkpoint inhibitor reinforc import immun system treat cancer
checkpoint inhibitor immun stimul agent cancer vaccin work activ allow t-cell
identifi cancer express tumor associ antigen taa car-t emerg one robust tool
immune-direct cancer attack involv engin t-cell recogn specif taa antigen
receptor combin antigen recognit fragment intracellular signal domain singl molecul
introduct t-cell -t produc lymphocyt high affin taa
car-t therapi valid fda approv clinic result shown car-t therapi effect
cancer possess certain molecular characterist b-cell cancer express overal car-t
approach treat malign valid approv novarti nyse nv kymriah
pediatric/young adult r/r b-cell gilead/kit yescarta adult r/r larg
b-cell lymphoma approv came ahead plan prescript drug user fee act pdufa date may
kymriah also approv treatment adult r/r larg b-cell lymphoma due unmet need
patient r/r b-cell larg b-cell lymphoma treatment approv rel small single-
arm studi thu potenti acceler path market mustang car-t therapi compar
convent cancer treatment refer primari efficaci analysi kymriah includ data patient
r/r b-cell b-cell lymphoma wherea yecarta primari efficaci analysi includ data
gener join heavi light chain variabl region monoclon antibodi provid antigen
recognit transmembran signal fragment normal part t-cell receptor complex encourag
t-cell activ prolifer fusion dna deriv antibody-produc b-cell t-cell
make receptor chimer exampl technolog develop memori sloan ketter mskcc juno
nation cancer institut nci kite univers pennsylvania upenn novarti shown
figur single-chain variabl fragment scfv antigen recognit domain extracellular
scfv-target element connect transmembran domain spacer note novarti kymriah
gilead/kit yescarta approv car-t therapi use murin scfv
mustang car-t candid use murin fulli human scfv addit antigen recognit domain
car-t human genet engin select
intracellular portion incorpor signal domain co-stimulatori molecul t-cell
requir t-cell receptor tcr engag signal well secondari co-stimulatori signal surviv
incorpor co-stimulatori signal domain allow multipl round t-cell prolifer improv
cytokin product drastic improv t-cell surviv mustang candid similar structur
depict depend candid use and/or costimulatori domain
figur schemat three
first-gener car-t therapi consist antibody-bas fragment signal domain
treatment show modest efficaci variou cancer primarili due insuffici expans persist
modifi cell second-gener car-t includ intracellular co-stimulatori domain
enhanc surviv increas prolifer engin cell base platform third-gener
construct util signal domain conjunct dual co-stimulatori element fourth
gener add base second-gener construct design recruit innat immun
cell intend target
often describ live treatment administ car-t cell prolifer vivo maintain antitumor
effector function sever month antigen recognit domain tailor address wide
varieti antigen promis clinic data report patient treat autolog car-t
target b-cell treatment acut lymphoblast leukemia larg b-cell lymphoma
sever antigen bcma psca egfrviii mesothelin
target compani expand applic car-t addit hematolog malign solid
tumor mustang pipelin consist car-t candid divers set liquid solid tumor antigen
therebi provid multipl shot goal
t-cell co-stimul normal condit t-cell activ requir two signal deliv antigen
present cell apc first signal occur bind tcr complex antigen ligand
stimul activ chain tcr bind co-stimulatori domain ligand apc
second signal promot expans antigen activ t-cell differenti effector
memori cell co-stimulatori domain enhanc product cytokin promot energi metabol
 et al chimer antigen receptor engin right step evolut adopt cellular
immunotherapi intern review immunolog
facilit cell-cycl case car-t activ one-step process intracellular portion
co-stimulatori molecul link extracellular scfv antigen bind trigger activ
co-stimulatori molecul co-stimulatori domain wide use
design valid approach exampl kymriah juno lead candid
use costimulatori domain wherea yescarta use co-stimulatori domain mustang develop
gener car-t therapi depend candid use and/or
engin manufactur car-t candid
car-t manufactur complex process initi develop small number patient academ
lab technolog sinc scale transfer commerci facil mustang build
squar foot cell process facil kite squar foot facil anticip creat treatment
patient annual univers massachusett medic campu worcest facilit core
manufactur step list complet mustang facil expect
leukapheresi patient lymphocyt separ peripher blood
activ t-cell activ use varieti method
transduct introduc t-cell use deliveri vehicl viru
expans phase genet modifi t-cell undergo round ex vivo expans use cell cultur
bioreactor achiev target dose
cell harvest cell collect wash cryopreserv
clinic trial confirm benefici effect administ lymphocyt deplet regimen prior car-t
dose lymphocyt deplet creat space lymphoid compart allow car-t cell engraft
expand lymphodeplet regimen also abil deplet suppress t-regulatori cell lympho-
condit liber pro-surviv cytokin allow t-cell select expand activ state note
celyad cyad shown activ car-t therapi without need
expect car-t therapi becom import therapeut option multipl form cancer potenti
therapi highlight sever collabor partnership acquisit taken place
figur show major deal occur juno kite cell design lab nanj legend privat celyad
cellecti cll includ academ collabor juno kite cell design lab
acquir last year car-t platform candid
sharp abba t-cell costimulation-biolog therapeut potenti challeng new england journal
medicin
figur partnership collabor acquisit car-t compani
acquir
acquir
acquir
ono novarti
transfer
acquir cash transact
acquir cash transact
acquir cash transact
 receiv world-wide licens co-
develop commerci lcar-
multipl myeloma
celyad grant exclus licens
ono japanes base compani
develop commerci
japan taiwan
licens allogen tcr-defici
car-t cell patent pertain two
celgen collabor
lead anti-bcma candid multipl
merck serono elect two initi car-
target candid reach
ind stage merck serono develop
commerci merck opt-in
independ
right pursu develop
total car-t target
compani coordin preclin
develop commerci
target total target
cellecti compani work
cellecti target cellecti work
independ addit target
acquir cash roughli
billion net cash market
secur juno share
own celgen time
acquir cash roughli
up-front
 paid up-front outsid
china cost-sharing/profit-
split agreement china split
term agreement celyad
receiv up-front payment
million potenti receiv
million mileston double-
digit royalti net sale note
total deal valu million
consist up-front payment
potenti develop
commerci mileston singl
digit royalti product sale
celgen pay develop
lead candid phase develop
next-gen candid celgen pay
mileston royalti payment
intrexon share econom provis
equal includ up-front payment
mileston royalti
cellecti receiv up-front plu
fund cost associ
pfizer-select target cellecti elig
receiv mileston payment
per product plu tier royalti
net sale commerci
product equiti agreement
purchas cellecti capit
newli issu share
allogen car-t collabor
effort underway gene-edit technolog modifi t-cell gener line allogen car-t
autolog car-t retain pre-exist tcr complex would like caus graft-versus-host diseas gvhd
infus patient donor risk gvhd consider roadblock gener
off-the-shelf car-t product also risk endogen immun system induc antibody-
mediat reject tumor reactiv t-cell hamper persist cellecti cll lead
allogen car-t compani gene edit technolog inactiv tcr constant region
modifi tcr gene key compon tcr complex intend elimin potenti
alloreact tcr thu minim gvhd
decemb enter licens agreement harvard univers allow
util technolog develop lab chad cowan ph develop differenti
car-t cell therapi term agreement mustang abl util technolog relat
develop allogen car-t cell gene edit platform enhanc tumor kill effici
t-cell persist one potenti target edit via case cancer
express t-cell neg effect tumor-kil effect lymphocyt follow engag
primarili express tumor cell mustang also enter research collabor agreement
beth israel deaco medic center bidmc allow dr cowan run preclin research program
mustang candid technolog spoke highli regard oncologist lot experi
car-t drug develop physician note allogen car-t similar safeti efficaci
rel autolog would favor sinc lot conveni easi use
second-gener car-t therapi util costimulatori domain
develop patient acut myeloid leukemia aml blastic plasmacytoid dendrit cell neoplasm
bpdcn hematolog diseas need improv therapi highlight fact
surviv aml patient bpdcn surviv year form cancer
high cell surfac express target partial valid clinic respons seen
compet therapi nasadg flotetuzumab stemlin
citi current evalu phase studi patient
relapsed/refractori aml bpdcn mustang plan begin studi treatment late
initi result studi provid oral present american societi
hematolog meet show complet respons treatment occur aml patient
bpdcn patient next updat program expect notabl
contain suicide-switch form truncat human egfr epitop allow deactiv
vivo case sever toxic via cetuximab anti-egfr monoclon antibodi
ration target cell surfac antigen overexpress leukemia progenitor/stem
cell low express normal hematopoiet stem cell monocyt endotheli cell
overexpress aml patient bpdcn patient glycoprotein
transmembran subunit receptor togeth form high affin il-
bound promot cellular prolifer surviv express primari aml
base upon signal transduc activ transcript express primari
aml correl poor diseas prognosi
aml cell target directli abil specif target cell
first analyz vitro cell deriv three aml patient
administ autolog blast deriv patient figur illustr abil car-t cell
differ recombin immunotoxin use scfv specif target lyse
posit cell aml patient cell treatment abl caus complet near complet lysi two three
aml patient sampl note aml well resolv heterogen
express cell indic specif cell
support lack activ seen use control
figur specif cell
display anti-leukem activ aml activ evalu
xenograft aml preclin model mice treat
phosphat buffer salin pb control evalu day later bioluminesc imag use measur
tumor burden shown figur day mice epitop
minim evid leukemia pb control treat mice higher number aml-deriv
tumor cell measur peripher blood togeth data highlight specif activ
tumor cell
figur activ xenograft aml model
safeti profil date patient evalu phase clinic studi preliminari safeti
inform avail treatment infus car-t cell well toler although
note dose still escal studi lack toxic seen point may part due
improv manag patient learn administ car-t therapi addit
increas implement roche/genentech vtx rog vx agent actemra tocilizumab help
mitig effect grade advers event dose-limit toxic
date grade neurotox event occur manag
revers also myeloabl effect observ mention contain suicide-
switch form truncat human egfr bind epitop allow deactiv vivo via
cetuximab case sever toxic mitig risk seriou advers event patient
studi requir immunologically-compat donor pick need emerg
acut myeloid leukemia aml aggress cancer blood bone marrow fatal left untreat
accord american cancer societi estim new case aml diagnos us
median age aml patient diagnosi year baby-boom gener age
number aml patient like increas aml common type adult acut leukemia expect
caus us death even aggress treatment aml often fatal accord
american cancer societi five-year overal surviv rate
pathogenesi caus aml
aml patient outgrowth cell myeloid lineag accumul bone marrow myeloid
cell predomin immatur white blood cell call myeloblast blast leukem cell bone
marrow cell dysfunct caus genet mutat impact normal differenti stem cell previou
treatment cytotox chemotherapeut agent radiat exposur common factor associ aml
sinc exposur mutagen agent may induc genet alter bone marrow stem cell
aml classif major classif system use categor patient aml origin
classif scheme french american british fab system origin propos fab
system classifi subtyp aml make distinct base upon type cell cancer
origin matur cancer cell updat system releas world
organ system group subtyp aml factor correl expect outcom
measur system also differ fab classif blast threshold suffici
aml diagnosi instead categori follow
acut myeloid leukemia recurr genet abnorm
acut myeloid leukemia multilineag dysplasia
acut myeloid leukemia myelodysplast syndrom therapy-rel
acut myeloid leukemia otherwis categor
addit histor classif system mani cancer includ aml also classifi base
presenc absenc particular genet mutat well-known mutat occur aml patient
gene inhibitor wild type mutat clinic develop
symptom diagnosi
accord nation cancer institut earli sign aml includ fever lethargi easi bruis bleed
weak weight loss fatigu visual symptom flat spot blood skin call petechia sever
method increas complex invas use diagnos aml complet blood count blood
smear provid analysi distribut cell within blood give initi pictur cellular imbal
diagnost test requir bone marrow aspir genet analysi blast medic diagnosi
aml requir greater leukem blast bone marrow featur abnorm hematocrit
abnorm platelet count also typic present
treatment aml
treatment program aml patient depend sever variabl includ patient age subtyp aml
whether diseas newli form recurr resist anoth import determin treatment
whether patient diseas fall one three risk categori better intermedi poor
three major step treatment aml cours diseas induct therapi consolid
therapi hematopoiet stem cell transplant hsct hsct involv intraven infus autolog
allogen stem cell collect bone marrow peripher blood umbil cord blood re-establish
hematopoiet function patient whose bone marrow immun system damag defect patient
undergo stage treatment time therapi determin success previou step
howev larg proport patient follow standard treatment cours exampl mani patient
unfit receiv intens chemotherapi regimen includ patient frail treatment varieti
bennett et al propos classif acut leukaemia french-american-british fab co-op
group british journal haematolog
jaff et al world organ classif tumour patholog genet tumour
haematopoiet lymphoid tissu lyon franc iarc press
reason especi advanc age patient known difficult time toler intens
chemotherapi median age aml close year overal cure rate patient
year age younger patient older
induct therapi patient choos treat receiv induct chemotherapi first line treatment
aml induct therapi intend reduc leukem blast return function bone marrow
commonli includ regimen call consist day cytarabin follow day anthracyclin
drug idarubicin daunorubicin mitoxantron cytarabin approv fda
nucleotid analog inhibit dna synthesi daunorubicin idarubicin metoxantron intercal agent
inhibit topoisomeras activ block dna synthesi antineoplast chemotherapeut drug caus
death rapidly-divid cell bodi target cancer cell also kill mani type cell
therefor induct therapi in-pati procedur usual week length must complet
hospit staff train requisit side effect high rate infect recent pharmaceut
vyxeo liposom daunorubicin cytarabin approv adult newli
diagnos therapi relat aml t-aml aml myelodysplasia-rel chang aml-mrc approv
base surviv advantag head-to-head studi
due damag effect induct therapi mortal high intens chemotherapi rang
younger aml patient old risk almost patient year
age opt palli care note all-caus vs day vs mortal
favor vyxeo number may adjust slightli treatment gain traction market
induct therapi often result cancer remiss defin blast concentr total blood compon
like residu blast surviv induct stage lead recurr therefor post-induct
treatment may administ use standard dose cytarabin
addit novarti nyse nv rydapt midostaurin inhibitor kinas enzym
approv combin treatment standard cytarabin daunorubicin induct
cytarabin consolid newly-diagnos aml mutat posit mutat occur roughli
aml patient pfizer nyse mylotarg gemtuzumab ozogamicin direct antibody-drug
conjug indic newly-diagnos r/r posit aml patient aml
estim posit
consolid therapi induct therapi follow consolid therapi high dose intermitt
cytarabin hidac everi hour day treatment paradigm chang sinc origin
descript
hematopoiet stem cell transplant ultim goal current treatment paradigm bridg patient
hsct usual indic consid aml patient relaps even complet
remiss howev patient elig hsct match donor found process
identifi elig patient match donor rigor treatment feasibl aml
patient relaps common sinc blast often fulli erad treatment make hsct
longo et al acut myeloid leukemia new england journal medicin
kantarjian therapi elderli patient acut myeloid leukemia cancer
mayer et al intens post-remiss chemotherapi adult acut myeloid leukemia cancer leukemia
group new england journal medicin
reliabl way extend overal surviv patient relaps follow allogen stem cell transplant
surviv rate roughli mustang evalu treatment patient r/r aml bpdcn
goal bridg patient transplant on-going citi phase i/ii trial
salvag therapi despit treatment aggress chemotherapi regimen mani aml patient never achiev
complet remiss mani experi relaps patient treat salvag
therapi may take differ form salvag therapi often includ toxic chemotherapi regimen
patient also encourag enter clinic trial stage identif proper salvag therapi patient
specif depend level remiss achiev patient age comorbid increasingli
recent therapi approv patient relapsed/refractori aml includ agios/celgen
celg idhifa enasidenib pfizer mylotarg idhifa inhibitor approv r/r
aml patient mutat occur aml patient
estim new case aml approxim death aml patient
overexpress case aml common form acut leukemia adult
standard care larg unchang decad leukemia type chronic myeloid leukemia
cml benefit target therapi gleevec imatinib sprycel dasatinib tasigna nilotinib iclusig
ponatinib bosulif bosutinib aml patient still undergo intens chemotherapi goal
achiev remiss patient relaps point sometim experienc multipl relaps result
aml patient expect surviv year accord american cancer societi
leav larg unmet need aml
market potenti aml market grow due recent approv vyxeo rydapt idhifa mylotarg
histor address gener car-t therapi like cost treatment
substanti novarti kymriah tisagenlecleucel approv patient younger year age r/r acut
lymphoblast leukemia adult r/r larg b-cell lymphoma gilead/kit yescarta
axicabtagen ciloleucel approv adult r/r larg b-cell lymphoma cost kymriah b-cell
patient respond within month treatment yescarta price patient
get conserv estim address market account number aml patient
receiv hsct annual approxim us eu assum
price/pati us eu address market could least billion billion
region respect addit patient undergo hsct may also elig
treatment note like compet therapi patient includ car-t
 like captur portion address market approv
plasmacytoid dendrit cell neoplasm bpdcn rare highli aggress form blood cancer character
uncontrol prolifer precursor plasmacytoid dendrit cell pdc estim roughli
new case bpdcn occur year us eu although could underestim consid
diseas often misdiagnos hematolog bpdcn common men middl
age elderli patient may also occur young adult children median surviv time newli diagnos
patient month although patient receiv stem cell transplant live much
approv product indic bpdcn current treatment mostli consist regimen use
aml
treatment drug fda approv treatment bpdcn current treatment consist
convent regimen use treat aml includ follow agents/combin
goal initi treatment bridg patient allogen autolog transplant chemotherapi induc
complet respons cr patient patient relaps within first healthi
patient achiev cr receiv transplant may prolong mani elderli patient elig
receiv high intens chemotherapi altern administ chop cyclophosphamid hydroxyl
doxorubicin vincristin prednison less intens treatment azacitidin less intens
therapi often insuffici bridg patient transplant
near-term approv bpdcn could stemlin target
recombinantli express fusion protein compris human conjug diphtheria toxin
on-going phase ii studi bpdcn patient respond treatment achiev
complet howev seriou toxic treatment observ includ fatal capillari
leak syndrom cl due encourag activ unmet need bpdcn grant
breakthrough design fda stemlin process submit roll bla therapi
overal result valid target bpdcn bode well mustang
julia et al plasmacytoid dendrit cell neoplasm clinic featur patient british journal dermatolog
kharfan-dabaja et al diagnost therapeut advanc blastic plasmacytoid dendrit cell neoplasm
focu hematopoiet cell transplant biolog blood marrow transplant
duff et al woman blastic nk cell leukemia/lymphoma achiev durabl remiss
hypercvad unrel umbil cord blood transplant clinic advanc hematolog oncolog
pemmaraju et al result pivot phase trial patient blastic plasmacytoid dendrit cell neoplasm
epidemiolog base world organ classif bpdcn identifi
acut myeloid leukemia aml relat precursor neoplasm exact incid diseas unknown
estim account hematolog malign cutan accord
leukemia lymphoma societi peopl us diagnos leukemia lymphoma
myeloma increas number patient eu diagnos
leukemia lymphoma myeloma assum similar rate growth hematolog
malign diagnos us eu peopl eu diagnos
cancer shown figur appli incid across leukemia lymphoma
myeloma case translat roughli newli diagnos case bpdcn per year us eu
median life expect someon bpdcn month estim preval
bpdcn us import keep mind incid bpdcn
like underestim patient diseas develop skin lesion common clinic
featur time note portion patient elig car-t treatment
figur incid preval bpdcn
annual patient leukemia lymphoma myeloma
patient bpdcn
total number bpdcn patient
clinic develop strategi
current evalu phase clinic trial aml bpdcn studi conduct
citi partner cancer center march initi phase data
present american societi hematolog annual meet decemb result
patient show complet respons occur aml patient bpdcn patient
primari object studi test safeti activ escal dose
pagano et al plasmacytoid dendrit cell neoplasm leukem present italian multicent studi
abreu-rodriguez et al epidemiolog hematolog malign annal oncolog
shi wang plasmacytoid dendrit cell neoplasm archiv patholog laboratori medicin
pagano et al plasmacytoid dendrit cell neoplasm leukem present italian multicent studi
cell initi result show treatment cell well toler notabl toxic event outsid
seen compet therapi neurotox fatal advers event next updat
trial expect
phase studi design singl center open-label dose escal phase trial evalu patient
relapsed/refractori aml persistent/recurr patient expect enrol one two
arm aml bpdcn decemb updat patient enrol
treat aml bpdcn donor-deriv autolog cell leukapheres peripher blood
lentivir transduc differ car-t studi use patient deriv cell prior
cell infus patient undergo lymphodeplet regimen fludarabin day
cyclophosphamid daili day
aml patient receiv one dose level car-t cell potenti second
dose continu meet safeti elig criteria still dose schema
clinic trial figur consid manufactur treatment occur citi
manufactur time car-t cell day total turnaround time roughli week
success rate updat primari endpoint studi safeti diseas
respons secondari endpoint includ engraft cell specif antibodi level
durat respons dor progress free surviv overal surviv os mustang plan begin
phase i/ii studi r/r aml bpdcn late
figur patient dose cell
preliminari phase data decemb patient aml bpdcn treat
patient characterist dose respons shown figur patient treat cell
achiev transient complet respons therapi last month prior relaps aml patient receiv
second dose level abl proceed hsct follow treatment one patient achiev
cr therapi remain mrd- follow allogen stem cell transplant given cur intent
anoth patient achiev cr lymphodeplet regimen remain cr follow
one patient bpdcn refractori treat cell patient achiev
cr remain month patient plan enrol higher dose correl studi
also on-going identifi potenti biomark respons resist well evalu express
level blast cell impact hematopoiesi overal result highlight activ
indic feasibl treatment option patient late stage aml bpdcn
figur result r/r aml bpdcn
day
flow
dim
term safeti treatment infus car-t cell well toler compar
target therapi although note dose still escal studi
grade advers event dose-limit toxic date neurotox
manag revers also myeloabl effect observ summari shown
figur note safeti concern rais target sinc endotheli toxic
capillari leak syndrom cl seen agent target cellecti
cll stemlin although earli develop capillari leak syndrom occur
yet patient treat incorpor suicid switch may help mitig risk
associ target base discuss key opinion leader potenti benefit
treatment outweigh risk patient aml bpdcn particularli poor prognosi current
figur summari r/r aml bpdcn
treatment develop aml bpdc
sever clinic trial underway test safeti efficaci new treatment aml recent advanc
field genom immunotherapi open new potenti therapeut avenu indic
drug therapi current clinic develop list figur primari differenti
factor develop program target patient popul sever program list
address patient specif dna mutat agio ivosidenib aml
daiichi sankyo tyo quizartinib aml type therapi often refer
person medicin becom feasibl due avail genom test develop
program util either cell- antibody-bas immunotherapi
figur select treatment develop aml
aml bpdcn
third gener autolog car-t-cel therapi phase i/ii develop r/r b-
cell non-hodgkin lymphoma technolog licens fred hutchinson cancer research center
septemb cell surfac receptor highli express malign cell immun cell
respons produc antibodi present antigen t-cell secret cytokin consid resist
treatment typic result antigen loss potenti applic follow progress
target agent like roch vtx rog vx rituxan addit could use
patient progress target car-t therapi poor candid target treatment
mustang open patient accrual trial notabl target car-t therapi
knowledg us clinic develop could signific valu driver mustang
background phosphoprotein express surfac b-cell patient live without b-cell
littl suggest long-term deplet result chronic treatment antibodi
increas patient risk develop cancer opportunist effect target
johnson et al mutat involv rituximab epitop rare diffus larg b-cell lympohma
signific caus r-chop failur haematologica
chen cohen live life without cell repeat b-cell deplet safe effect long-term treatment
plan rheumatoid arthriti intern journal clinic rheumatolog
b-cell malign autoimmun diseas valid success roch rituxan rituximab
sale excess billion rituxan approv follow indic though also use off-
label diseas multipl sclerosi ms
granulomatosi polyang gpa
potenti use cell malign
rituxan work bind destroy cancer cell antibody-depend cell-medi cytotox
complement-depend cytotox though effect patient respond treatment
mani develop respons rate rituxan monotherapi patient relaps indol nhl
chemotherapy-nav patient howev rituxan often use combin cyclophosphamid
doxorubicin vincristin prednison r-chop lead respons rate
studi assess exact mechan rituxan resist cell malign suggest infrequ
caus antigen loss rather factor includ high level promot rituxan
intern ultim reduc clinic efficaci sinc design effect insid
initi develop r/r b-cell non-hodgkin lymphoma patient would like
activ target car-t develop ex-u highlight potenti activ overal
could effect option patient progress therapi support
clinic activ use target car-t therapi china phase iia studi conduct evalu
autolog car-t patient r/r b-cell lymphoma fail prior line
patient enrol studi receiv cytoreduct chemotherapi debulk
tumor deplet exist lymphocyt shown figur patient diffuse-larg cell lymphoma
dlbcl follicular lymphoma fl mantl cell lymphoma mcl anoth primari margin
zone lymphoma pcmzl orr treat patient achiev cr median
greater month patient experienc cr month importantli sever toxic
observ could point differenti target car-t therapi b-cell malign
boross leusen mechan action antibodi american journal cancer research
roghanian et al resist futil target inhibitori maxim immunotherapi
dotan et al impact rituximab rituxan treatment b-cell non-hodgkin lymphoma pharmaci
lim et al fc gamma receptor iib target cell promot rituximab intern reduc clinic efficaci
johnson et al mutat involv rituximab epitop rare diffus larg b-cell lymphoma
signific caus r-chop failur haematologica
zhang w-i et al treatment chimer antigen receptor-modifi cell patient relaps
refractori b-cell non-hodgkin lymphoma earli phase iia trial report natur
figur activ target car-t r/r nhl
non-hodgkin lymphoma nhl common form lymphoma affect cell cell
diseas begin lymphocyt form white blood cell found lymphat system
often present organ outsid lymph node time diagnosi roughli nhl case occur b-
cell affect t-cell accord american cancer societi estim peopl
us diagnos nhl die diseas estim
addit patient diagnos annual eu subtyp nhl classifi
world organ although shown figur subtyp make roughli
treatment paradigm nhl differ base subtyp diseas typic includ combin
rituxan cyclophosphamid doxorubicin vincristin prednison r-chop follow stem-cel
three prognost group nhl call indol aggress highli aggress lymphoma patient
indol diseas rel good prognosi median overal surviv year although
patient late stage diseas often curabl patient aggress highli aggress nhl much
quicker progress indol diseas overal surviv rate patient nhl
armitag et al new approach classifi non-hodgkin lymphoma clinic featur major histolog
subtyp journal clinic oncolog
figur main type nhl preval
aggress form diseas mostli affect individu
age organ outsid lymph node involv
approxim diagnos genet error
fa often link diseas develop
present indol aggress form diseas
roughli turn dlbcl often occur multipl
lymph node site addit bone marrow frequent
character transloc chromosom
aggress form diseas common men
women often involv bone marrow lymph node spleen
gi system identifi presenc cyclin protein
genet abnorm lymphoma cell involv chromosom
close relat cll indol form diseas
indol form diseas occur mucosa associ
lymphoid tissu mostli found stomach link
infect helicobact pylori
aggress form diseas often affect young adult
indol form diseas often present bone marrow
lymph node spleen mani time diagnos
detect high level protein blood
indol form diseas often present bone marrow
spleen blood character delet mutat
treatment non-hodgkin lymphoma
shown figur treatment paradigm nhl base stage subtyp diseas indol
lymphoma like follicular lymphoma cure radiat therapi alon earli stage diagnos late
stage nhl patient curabl patient late stage diseas often respons treatment rituxan
without combin cyclophosphamid doxorubicin vincristin prednison r-chop
cyclophosphamid vincristin prednison r-cvp patient may also receiv stem cell transplant follow
mainten rituxan roch gazyva obinutuzumab next-gener antibodi approv treat
patient previous untreat cll sever set follicular lymphoma gazyva shown superior
armitag et al new approach classifi non-hodgkin lymphoma clinic featur major histolog
subtyp journal clinic oncolog
rituxan treat patient treatment nave follicular lymphoma phase studi
could use place rituxan patient form
figur treatment paradigm nhl
radiat alon may cur fl
diseas form
differ chemotherapi monoclon
radiat patient
chemotherapi chop rituxan
cell subtyp cycl
hematopoiet stem cell transplant elig
patient respond second line treatment poor prognosi enrol clinic trial
receiv car-t therapi kymriah yescarta approv treatment adult patient r/r larg
b-cell lymphoma line system therapi clinic data yescarta r/r larg b-cell lymphoma
show orr patient experienc cr median durat respons
month although median reach last data readout patient experienc cr although
effect sever advers event sae cytokin releas syndrom neurotox caus
car-t treatment limit use late-lin set overal patient refractori aggress nhl
poor prognosi retrospect analysi prior approv car-t refractori patient dlbcl
orr median surviv
 et al obinutuzumab-bas induct mainten prolong progression-fre surviv patient
previous untreat follicular lymphoma primari result random phase gallium studi american societi
hematolog
crump et al outcom refractori aggress diffus larg b-cell lymphoma dlbcl result intern
epidemiolog american cancer societi estim approxim peopl us
diagnos nhl die diseas estim addit patient
diagnos year patient nhl express despit initi
efficaci around patient eventu progress r-chop patient
remain patient undergo stem-cel transplant follow progress first-lin therapi
roughli relaps initi develop patient r/r b-cell nhl fail least
therapi relaps follow stem cell transplant dlbcl aggress form nhl
common account case gilead estim roughli patient us year
refractori dlbcl elig therapi assum price tag translat annual
market opportun billion us alon
mention could use patient progress target car-t therapi
registr trial yescarta patient respond primari treatment
patient remain respons month thu sever potenti nhl patient popul mb-
could use
phase i/ii studi design open-label single-arm dose-escal phase i/ii investig sponsor studi
fred hutchinson cancer research center recent began evalu patient r/r cell non-
hodgkin lymphoma million trial fund mustang studi plan
enrol adult patient compris number posit b-cell nhl mantl cell follicular
lymphoplasmacyt margin zone transform indol cell lymphoma dlbcl treatment process
consist leukapheresi follow lymphodeplet use cyclophosphamid without fludarabin
hour cell infus back patient one sever escal dose need patient
receiv low-intens chemotherapi lenalidomid ibrutinib control diseas prior infus mb-
primari endpoint studi determin maximum toler dose secondari endpoint
includ safeti orr
compet treatment develop r/r nhl
gener antibodi compet strategi evalu circumv rituxan
resist one develop third-gener antibodi roch gazyva obinutuzumab
induc cell death natur killer nk cell induc antibody-depend cellular cytotox adcc
plosker figgitt rituximab review use non-hodgkin lymphoma chronic lymphocyt
armitag treatment approach patient diffus larg b-cell lymphoma mayo clinic proceed
gisselbrecht et al salvag regimen autolog transplant relaps larg b-cell lymphoma
rituximab era journal clinic oncolog
sub-set rituxan resist lymphoma gazyva current approv first line treatment cll sever
fl set novarti nyse nv arzerra ofatumumab second-gener antibodi approv
treatment cll shown activ patient follicular lymphoma refractori rituxan despit
arzerra inferior rituxan certain patient
polatuzumab vedotin roch random phase ii result present american societi
hematolog meet combin polatuzumab vedotin combin rituximab
bendamustin patient r/r dlbcl unfit hsct result show cr rate
patient receiv polatuzumab vedotin increas cr rate accompani
increas os month month roch current conduct pivot phase studi
polatuzumab vedotin r-chop front-lin dlbcl
selinexor dlbcl karyopharm karyopharm present updat data
european hematolog associ eha meet open label random phase iib studi lead asset
selinexor antagonist relapsed/refractori diffus large-b cell lymphoma march
data cutoff patient receiv mg selinexor monotherapi patient receiv mg selinexor
monotherapi half patient receiv dose selinexor germin center b-cell gcb
lymphoma patient gcb-deriv diseas typic better prognosi without gcb statu
median number prior regimen patient cohort receiv
shown figur patient receiv mg mg selinexor similar respons rate determin
independ central radiolog review show activ independ gcb statu orr evalu
patient patient experienc cr addit patient achiev stabl diseas
clinic meaning consid prognosi patient popul respons treatment occur quickli
median time respons month posit patient late-stag diseas sinc
identifi effect treatment short time-frame crucial median overal surviv among treat patient
month
figur best respons treatment selinexor
maloney et al phase studi ofatumumab vs rituximab indol b-cell non-hodgkin lymphoma relaps
rituximab-contain therapi homer result interim analysi european hematolog associ abstract
term safeti mg dose selinexor better toler mg dose common grade
mg arm thrombocytopenia neutropenia anemia fatigu
leukopenia anorexia nausea base safeti efficaci dose test compani previous
amend studi discontinu dose mg arm compani plan enrol addit patient
r/r dlbcl receiv mg selinexor
direct car-t gbm
second-gener car-t recogn membrane-teth ligand
develop r/r glioblastoma multiform gbm citi evalu treatment open-label
non-random phase studi patient r/r gbm result use intracerebroventricular icv administr
old patient highli aggress recurr gbm studi publish new england journal
medicin decemb patient poor prognosi achiev complet resolut intracrani
spinal lesion follow icv infus car-t cell provid evid target
result clinic respons although singl case report result encourag sinc activ
car-t treatment solid tumor histor compromis suppress tumor microenviron
util memori enrich t-cell lentivir transduc express specif
truncat
rational target one biggest challeng develop car-t cell immunotherapi
solid tumor identif tumor antigen highli express tumor cell surfac normal life-
sustain tissu potenti target gbm overexpress gbm tumor
express signific level normal brain express increas diseas progress
associ poor prognosi normal cell bind monom low affin
bind requir hetero-dimer high affin bond heterodim complex goe
trigger downstream pathway activ exert transcript control gene contain
arrest specif promot involv gbm tumor cell express
bind higher affin higher affin bind allow sequestr
away
human glioblastoma model nsg mice effect evalu plate-bound recombin human
stimul car-t cell produc mb-
demonstr much stronger respons human compar human
indic specif cancer associ antigen car-t cell also demonstr stronger respons
 et al optim chimer antigen receptor t-cell improv anti-tumor
efficaci glioblastoma molecular therapi pp
 et al signific receptor alpha target glioblastoma therapi neurooncolog pp
 et al signific receptor alpha target glioblastoma therapi neurooncolog pp
human compar mock-transduc t-cell result summar
figur show effici lyse human gbm tumor line exhibit high level
express effector activ tumor line express significantli differ
mock-transduc t-cell
optim clinic paramet translat car-t cell therapi patient evalu use mous xenograft
brain tumor model nsg mice receiv cell intra-crani engraft
period cell engin express firefli luciferas ffluc report gene dexamethason larg use
gbm patient manag symptom brain edema therefor effect corticosteroid
car-t cell therapi need establish brain tumor induc mice receiv either high mg/kg mid
mg/kg low mg/kg level dexamethason week simultan one dose
administ day loss t-cell mediat effect seen highest dose group lead
conclus anti-tumor effect maintain conjunct low-dos
nsg mous brain tumor model also use assess two differ method treatment deliveri intraven
infus intracrani infus multifoc gbm model develop inject ffluc tumor
cell left right hemispher compar intraventricular intracrani deliveri icv tumor site
intracrani deliveri ict mice receiv infus either icv right ict administr
effect inhibit tumor growth right hemispher icv administr prove effici
affect growth contralater tumor left hemispher figur demonstr reduct
tumor size deliveri method contrari intraven administr demonstr therapeut
 et al optim chimer antigen receptor t-cell improv anti-tumor
efficaci glioblastoma molecular therapi pp
 et al optim chimer antigen receptor t-cell improv anti-tumor
efficaci glioblastoma molecular therapi pp
figur tumor reduct icv vs ict deliveri
accord american cancer societi estim patient diagnos brain nervou
system cancer unit state result gbm common type
malign brain tumor account case surviv rate diseas
glioma type brain tumor develop glial cell star-shap cell support nerv cell
four type glial cell includ astrocyt oligodendrocyt microglia ependym cell astrocytoma
primari brain tumor aris astrocyt brain gbm also known grade iv astrocytoma base
histolog common difficult brain tumor treat highli invas glial tumor spread
nearbi tissu rapidli frequent cross midlin contralater brain case gbm develop
rapidli elderli patient consid primari glioblastoma patient prior clinic histolog
evid malign brain lesion approxim case secondari glioblastoma progress
preexist low-grad astrocytoma anaplast astrocytoma
pathogenesi molecular basi gbm
caus gbm remain unknown unlik mani type cancer smoke diet implic
caus alcohol radiat exposur toxin among possibl risk viru
recent identifi anoth potenti caus gbm may assert carcinogen effect suppress
transcript properti tumor suppress
zheng et al risk brain cancer associ cigarett smoke use tobacco product iowa
cancer epidemiolog biomark prevent
huncharek et al dietari cure mean risk adult glioma meta-analysi nine observ studi journal
environment patholog toxicolog oncolog
baglietto et al alcohol consumpt risk glioblastoma evid melbourn collabor cohort
studi intern journal cancer
ohgaki kleihu epidemiolog etiolog glioma acta neuropathologica
vilchez bute oncogen
gbm normal aris glial cell brain primarili resid white matter one two main
compon central nervou system white matter contain glial cell nerv fiber axon mani axon
surround type fat tissu call myelin give white matter characterist color main
compon brain gray matter primarili compos neuron cell bodi along dendrit glial
cell capillari neuron cell bodi capillari give gray matter color white matter modul
distribut action potenti coordin commun differ brain region wherea gray
matter associ process cognit gbm grow rapidli case may appear differ via
mri depend featur amount hemorrhag necrosi
diagnosi screen offici gbm treatment guidelin
glioblastoma diagnos via neurolog exam detail brain scan distinguish gbm-associ brain
lesion associ multipl sclerosi acut stroke brain metastas cancer mri
gold standard imag brain tumor due lower resolut ct scan gener use mri
access stereotact biopsi craniotomi tumor resect commonli perform confirm
diagnosi stereotact biopsi employ three-dimension stereo imag guid needl precis remov
tissu examin microscop wherea craniotomi surgic procedur access brain
temporarili remov bone flap skull
gbm standard current standard care newli diagnos gbm surgic resect tumor
follow radiat illustr figur procedur may repeat recurr
tumor surgic intervent gener focus remov de-bulk much tumor mass possibl
total resect cur surgeri virtual imposs due infiltr natur tumor critic natur
surround central nervou system tissu chemotherapi temodar temozolomid combin
radiat fda approv therapi newli diagnos gbm genentech/roch vtx rog vx avastin
bevacizumab receiv fda approv base durabl object respons second-lin therapi patient
fail prior treatment fail provid surviv advantag point cours treatment
sometim receiv avastin patient encourag receiv experiment therapi clinic trial
random control trial demonstr avastin plu standard front-lin therapi lead
surviv benefit newli diagnos gbm use nearli gbm patient suffer
relaps cancer follow front-lin treatment median overal surviv os patient first
recurr
nccn guidelin central nervou system cancer version
gilbert et al random trial bevacizumab newli diagnos glioblastoma new england journal
chinot et al bevacizumab plu radiotherapy-temozolomid newli diagnos glioblastoma new england
journal medicin
friedman et al bevacizumab alon combin irinotecan recurr glioblastoma journal clinic
figur current standard gbm
epidemiolog gbm rapidli progress almost univers fatal brain tumor affect approxim
new individu year surgic intervent follow temodar radiat gener
first cours treatment newli diagnos gbm almost gbm patient progress chemoradi
avastin current second-lin therapi europ incid gbm treatment rate physician
similar us target overexpress gbm tumor
trial design open-label non-random phase studi evalu patient r/r
trial conduct citi partial fund million grant california
institut regen medicin cirm provid signific cost save mustang patient plan
enrol follow strata evalu dose level
stratum biopsi intratumor inject
stratum resect intracav ict inject
ostrom et al cbtru statist report primari brain central nervou system tumor diagnos unit
state neuro-oncolog
time leukapheresi dose expect day dose occur day
potenti addit infus occur radiograph imag done everi day assess chang
tumor volum primari endpoint studi safeti secondari endpoint includ tumor regress chang
cytokin level chang car-t cell level orr os chang qualiti life cell detect tumor
antigen express level
preliminari data new england journal medicin initi result use iv ict deliveri
result object respons howev posit result old patient recurr gbm
receiv icv studi publish new england journal medicin decemb patient
poor prognosi multifoc leptomening diseas histolog featur dedifferenti glioblastoma
prolif rate patient initi present glioblastoma right tempor lobe
place standard-of-car therapi consist tumor resect radiat temozolomid month post-
diagnosi mri pet scan reveal glioblastoma recurr patient subsequ enrol
phase studi car-t cell manufactur rapid diseas progress lead develop
multifoc leptomening glioblastoma involv cerebr hemispher prior initi first treatment
cycl patient underw resect largest tumor right tempor occipit region tumor two
smaller tumor left tempor lobe tumor remain two tumor left tempor lobe tumor
left untouch
treatment cycl patient receiv initi intracav infus t-cell follow weekli
intracav infus t-cell infus direct resect caviti tumor
cathet safeti efficaci assess conduct third sixth dose tumor remain stabl
day surgeri without diseas progress howev mri reveal diseas progress tumor
well two new lesion tumor near previous resect region new metastat lesion
note spine tumor figur show diseas progress first treatment cycl overal intracav
deliveri cycl effect local tumor suppress suffici tumor control recurr
prevent distant site
 et al regress glioblastoma chimer antigen receptor t-cell therapi new england journal
medicin pp
figur mri result follow intracav infus car t-cell
treatment cycl patient subsequ receiv intraventricular infus consist initi dose
 car t-cell follow weekli intraventricular infus car t-cell right later
ventricl dramat reduct intracrani spinal lesion seen infus mri pet scan
follow infus demonstr decreas tumor addit infus led complet
resolut tumor mri pet figur summar reduct tumor size across initi
observ tumor dramat clinic respons maintain month follow treatment initi
none origin tumor recur treatment cycl also saw gradual elimin system dexamethason
greatli improv qualiti life allow patient return normal although singl patient
case report provid proof-of-concept gbm effect target car-t
 et al regress glioblastoma chimer antigen receptor t-cell therapi new england journal
medicin pp
figur reduct spinal intracrani tumor follow intraventricular car t-cell infus
safeti profil intraventricular intracav infus deliv maximum dose
cell appear well toler grade higher advers event report possibl treatment-
relat grade event appear within hour infus includ headach gener fatigu myalgia
olfactori incid grade advers event correl increas inflammatori
cytokin absenc system toxic effect compar gener associ anti-tumor respons
high diseas burden patient receiv car-t cell therapi demonstr favor safeti profil
 et al regress glioblastoma chimer antigen receptor t-cell therapi new england journal
medicin pp
treatment develop gbm
sever clinic trial underway test safeti efficaci new treatment gbm drug
therapi current late stage clinic develop list figur gbm treatment
develop specif patient popul part due small number driver mutat found gbm patient
figur select treatment develop gbm
recurr first-
target express cancer cell gbm
second gener car-t-cel therapi develop initi use glioblastoma
breast cancer metastas brain technolog in-licens citi june
exclus licens agreement express seen gbm patient provid
rational explor target antigen car-t therapi preclin result announc octob
demonstr abil kill tumor cell intraventricular deliveri show activ multifoc
brain metastasi mustang plan launch first-in-human phase clinic trial metastat breast
cancer brain compani plan eventu explor dual therapi gbm combin mb-
acknowledg target car-t therapi could result on-target off-
tumor toxic result low appreci amount normal tissu express although
yet seen aurora biopharma privat also develop target car-t
 et al region deliveri chimer antigen receptor-engin cell effect target breast
cancer metastasi brain clinic research pp
background epiderm growth factor receptor member human epiderm
growth factor receptor famili play central role cell growth surviv differenti
implic trigger varieti signal pathway lead compris cysteine-rich
extracellular ligand bind site transmembran segment intracellular domain tyrosin kinas catalyt
activ receptor exist monom undergo dimer upon ligand bind dimer result
auto-phosphoryl tyrosin residu mainli initi mapk pkc pathway addit
signal pathway target express invas breast cancer
viabl therapeut target valid success approv direct monoclon
antibodi roch vtx rog vx herceptin trastuzumab antibodi drug conjug adc
roch kadcyla trastuzumab emtansin breast cancer
target car-t therapi preclin develop treatment multipl myeloma
also known receptor activ cytotox cell cracc novel member signal
lymphocyt activ molecul famili nk cell receptor regul immun function
also express cell cell dendrit cell nk-t cell monocyt select express
surfac plasma cell high express multipl myeloma cell notabl express correl
molecular classif target would restrict particular mm lack
express major organ minim risk potenti seriou side effect associ car-t cell
therapi on-target off-tumor toxic ind submiss phase i/ii trial multipl
myeloma expect begin late
prostat stem cell antigen psca target car-t therapi preclin develop prostat
pancreat bladder gastric cancer technolog licens citi june psca small
glycosylphosphatidylinositol -anchor cell surfac protein member famili
anchor protein express surfac psca express epitheli cell
prostat urinari bladder kidney skin esophagu stomach placenta physiolog function psca yet
elucid knockout mice model show gross abnorm patholog potenti mechan
function hypothes base structur psca contain activin type i/ii extracellular receptor domain
capabl bind superfamili ligand initi downstream signal structur also incorpor gpi-
anchor upon cleavag releas psca membran allow function receptor-
mediat signal pathway psca origin found overexpress prostat
iqbal epiderm growth factor receptor cancer overexpress therapeut
 et al express breast cancer primari tumour correspond metastas origin data
literatur review british journal cancer pp
 et al potenti new therapeut antibodi target treatment multipl myeloma clinic cancer
 et al prostat stem cell antigen psca jekyl hyde molecul clinic cancer research pp
 et al prostat stem cell antigen cell surfac marker overexpress prostat cancer proceed nation
academi scienc unit state america pp
investig led discoveri antigen also up-regul urinari bladder cancer renal cell
carcinoma pancreat cancer associ up-regul over-express make attract therapeut
target specif cancer treatment note bellicum blcm evalu psca car-t treatment
phase trial
manufactur timelin could import role market penetr time car-t therapi
primarili develop patient relapsed/refractori diseas consid patient diseas state
near death poor prognosi time take remov patient cell infus car-t
cell could play critic role outcom overal qualiti life shown figur gilead/kit yescarta
leader turnaround time vein-to-vein time laps day mustang process optim
manufactur capabl mention vein-to-vein time week could
competit field note compani advanc car-t candid mb-
may provid first mover advantag select indic discuss report mustang look
differenti car-t therapi go novel car-t target use knockout
cell combin car-t therapi line immune-oncolog small molecul antibodi
perform cell process step worcest facil
figur vein-to-vein time select car-t therapi
still optim
week
switch car-t therapi commerci set difficult host event
well-regard physician heavili involv initi develop car-t therapi note
despit approv car-t therapi novarti gilead/kit expect second third
market car-t therapi much barrier use overal felt hospit infrastructur
place switch car-t treatment somewhat easi physician use therapi
manufactur quickest favor safeti efficaci note futur car-t therapi
may need run bigger studi around patient approv need novarti kymriah
receiv approv thu may greater barrier market entri time barrier
switch car-t note kol feel physician stick singl product per indic
use sever cancer type
fear enough icu bed car-t patient like overblown one concern
rais regard commerci launch car-t therapi enough intens care unit icu
bed avail support inflow patient receiv car-t therapi depend cancer type
roughli half patient treat car-t requir icu care spoke highli regard oncologist
heavili involv clinic develop kymriah physician note base experi
patient end icu car-t relat advers event make small percentag bed capac
doesnt see icu capac issu overal kol believ perform car-t procedur
per month like high end treat physician mention one place bottleneck
may occur car-t commerci launch relat need intervent radiologist extract cell
pediatr patient via apheresi cathet
intellectu properti licens deal
mustang exclus licens agreement citi fred hutchinson cancer research center
harvard univers car-t therapi relat technolog elig
receiv annual fee addit potenti mileston payment roughli million
mid-singl digit royalti net sale mustang also elig pay mid-teen mid-thirti
percentag certain revenu connect sublicens psca technolog licens
mustang paid up-front fee rang million million pay annual mainten
fee respect institut start potenti mileston payment million may
also due well mid-singl digit royalti net sale
compani enter licens agreement ucla ip relat engin anti-prost stem
cell antigen antibodi mustang paid ucla up-front fee million owe annual mainten fee
first two year year three four thereaft potenti mileston
payment total million ucla entitl royalti payment mid-singl digit net
product sale mustang paid fred hutch million up-front annual mainten fee
potenti mileston payment million may due addit mid-singl digit royalti net product
sale mustang recent announc licens agreement harvard univers use develop
off-the-shelf car-t therapi addit gene edit platform
dr litchman serv presid chief execut offic member mustang board
director sinc april dr litchman join mustang llc serv presid chief
execut offic dr litchman oversaw advanc compani pipelin protein-
degrad therapeut treatment cancer diseas toward investig new drug
applic well execut multi-target discoveri collabor merck genentech prior
dr litchman spent year novarti pharmaceut corpor held posit
increas respons relat develop novarti oncolog pipelin recent dr litchman
serv senior vice presid execut global program head cell gene therapi
led collabor univers pennsylvania investig chimer antigen receptor modifi cell
ts direct cell malign prior collabor dr litchman serv
novarti vice presid head oncolog busi develop licens earlier career dr litchman
senior equiti analyst ursu capit direct oncolog immunolog clinic research hoffmann-la
roch inc dr litchman receiv yale univers school medicin princeton
univers complet intern medicin resid hematology-oncolog fellowship new york-
vice presid financ corpor control
mr achenbach serv vice presid financ corpor control sinc novemb mr
achenbach bring mustang year experi financ account includ approxim
year pharmaceut medic product industri recent mr achenbach serv vice presid
corpor control amerigen pharmaceut limit oversaw financ account function
compani establish commerci organ china prior mr
achenbach serv vice presid financ america vice presid global financi plan
analysi convatec group plc global medic product technolog compani led financ
account oper canada south america earlier career mr achenbach held role
increas respons financ account andrx corpor acquir watson
pharmaceut inc ivax corpor acquir teva pharmaceut ltd mr
achenbach hold financ roosevelt univers chicago econom
univers florida gainesvil
chairman board
mr weiss serv chairman board director sinc may mr weiss serv sever capac
fortress biotech recent serv execut vice chairman sinc februari also serv
execut chairman presid chief execut offic inc compani found
mr weiss current co-portfolio manag opu point llc co-found
mr weiss chairman chief execut offic keryx biopharmaceut inc
help compani acquir develop lead drug auryxia well execut strateg allianc
auryxia japan tobacco inc torii pharmaceut co ltd worth million mr weiss serv
chairman board director nation hold corpor mr weiss began
profession career lawyer cravath swain moor llp earn columbia law school
 financ univers albani
relationship fortress tech may allow effici drug develop fortress tech
compani fortress close heavili involv development progress product candid within
subsidiari compani shown figur includ provid fund manag servic regard
busi develop account financ clinic trial execut scientif affair manufactur legal
experienc board member addit fortress maintain super-major vote share subsidiari
mean fortress retain full control execut decis forward direct subsidiari process
allow effici drug develop mustang may result substanti cost save throughout
figur fortress fund manag support subsidiari compani
risk invest
consid invest high-risk invest develop stage compani
histori take treatment market current fda approv drug portfolio
sever compani tri target indic mustang creat market competit mustang lead
program yet gener pivot data limit clinic data date furthermor earli indic
efficaci necessarili translat posit late-stag result compani mustang may unabl
obtain suffici capit fund plan develop program regulatori risk associ
develop drug mustang may receiv fda approv candid despit signific time
financi invest regulatori approv market sell drug guarante drug penetr
market sale may meet expect investor
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect
secur subject compani research analyst cover research view express report accur
reflect person view subject secur subject compani part research
analyst compens directli indirectli relat specif recommend view express research
analyst report
